Engineering of CoA‐Acylating Butyraldehyde Dehydrogenase for Enhanced 1,3‐Butanediol Production in Escherichia coli
Biotechnology and Bioengineering · 2026-06 · 123 (6) · 1605-1614
DOI: 10.1002/bit.70197 ↗At a glance
Journal article in Biotechnology and Bioengineering, published online on 2026-03-25. Written by Seunghyun Cho and 5 co-authors. Institution: School of Energy and Chemical Engineering, Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea. Major MEDLINE topics: Butylene Glycols, Escherichia coli, Aldehyde Oxidoreductases, Metabolic Engineering. 27 references. The full text is freely available (open access, CC BY 4.0). Funded by: Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Ministry of Health and Welfare, Republic of Korea.
Abstract (original language)
Microbial production of 1,3‐butanediol (1,3‐BDO) offers a renewable route to this versatile C 4 chemical. However, the low performance of CoA‐acylating butyraldehyde dehydrogenase (Bld), which contains a catalytic cysteine, limits efficient production in recombinant Escherichia coli ( E. coli ). In this study, wild‐type Clostridium saccharoperbutylacetonicum Bld and its variant Bld* were biochemically characterized and engineered to improve conversion of 3‐hydroxybutyryl‐CoA (3‐HB‐CoA) to 3‐hydroxybutyraldehyde (3‐HBA). Enzyme activity was strongly reduced by the product, 3‐HBA, and this reduction was largely alleviated by added cysteine. To mitigate this interference, several noncatalytic cysteine residues in Bld* were substituted individually and in combination guided by multiple sequence alignment and machine‐learning‐based mutational prediction. The triple mutant C151N/C189A/C353L (designated CYS31) displayed ~30% higher specific activity without altering substrate affinity or selectivity. Incorporation of CYS31 into a 1,3‐BDO‐producing E. coli strain led to a corresponding ~30% increase in titer, indicating that enhanced in vitro kinetics translated to higher in vivo 1,3‐BDO production. These findings provide a more effective Bld variant for 1,3‐BDO production and demonstrate that non‐active‐site cysteine residues can be viable engineering targets when an aldehyde intermediate is involved.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Energy and Chemical Engineering, Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea.
- R&D Center, ACTIVON Co. Ltd., Cheongju, Republic of Korea.
ORCID profiles: Sunghoon Park
Funding
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI)
- Ministry of Health and Welfare, Republic of Korea
Cite
APA
Cho, S., Islam, T., Islam, S., Lee, J., Jung, S. W., & Park, S. (2026). Engineering of CoA‐Acylating Butyraldehyde Dehydrogenase for Enhanced 1,3‐Butanediol Production in Escherichia coli. Biotechnology and Bioengineering, 123(6), 1605-1614. https://doi.org/10.1002/bit.70197
Vancouver
Cho S, Islam T, Islam S, Lee J, Jung SW, Park S. Engineering of CoA‐Acylating Butyraldehyde Dehydrogenase for Enhanced 1,3‐Butanediol Production in Escherichia coli. Biotechnology and Bioengineering. 2026;123(6):1605-1614. doi:10.1002/bit.70197
BibTeX
@article{Cho2026,
author = {Cho, Seunghyun and Islam, Tayyab and Islam, Sobia and Lee, Junhak and Jung, Sung Won and Park, Sunghoon},
title = {Engineering of CoA‐Acylating Butyraldehyde Dehydrogenase for Enhanced 1,3‐Butanediol Production in Escherichia coli},
journal = {Biotechnology and Bioengineering},
year = {2026},
volume = {123},
number = {6},
pages = {1605--1614},
doi = {10.1002/bit.70197}
}
EUVIMED